Literature DB >> 11283805

Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes.

E Lautenbach1, J B Patel, W B Bilker, P H Edelstein, N O Fishman.   

Abstract

The prevalence of antibiotic resistance among extended-spectrum beta-lactamase (ESBL)--producing Escherichia coli and Klebsiella pneumoniae has increased markedly in recent years. Thirty-three patients with infection due to ESBL-producing E. coli or K. pneumoniae (case patients) were compared with 66 matched controls. Total prior antibiotic use was the only independent risk factor for ESBL-producing E. coli or K. pneumoniae infection (odds ratio, 1.10; 95% confidence interval, 1.03--1.18; P=.006). Case patients were treated with an effective antibiotic a median of 72 hours after infection was suspected, compared with a median of 11.5 hours after infection was suspected for controls (P<.001). ESBL-producing E. coli or K. pneumoniae infection was associated with a significantly longer duration of hospital stay and greater hospital charges (P=.01 and P<.001, respectively). Finally, many ESBL-producing E. coli and K. pneumoniae isolates were closely related. ESBL-producing E. coli and K. pneumoniae infections have a significant impact on several important clinical outcomes, and efforts to control outbreaks of infection with ESBL-producing E. coli and K. pneumoniae should emphasize judicious use of all antibiotics as well as barrier precautions to reduce spread.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11283805     DOI: 10.1086/319757

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  194 in total

1.  Molecular epidemiology over an 11-year period (2000 to 2010) of extended-spectrum β-lactamase-producing Escherichia coli causing bacteremia in a centralized Canadian region.

Authors:  Gisele Peirano; Akke K van der Bij; Daniel B Gregson; Johann D D Pitout
Journal:  J Clin Microbiol       Date:  2011-12-07       Impact factor: 5.948

Review 2.  Recent developments in beta lactamases and extended spectrum beta lactamases.

Authors:  Joumana N Samaha-Kfoury; George F Araj
Journal:  BMJ       Date:  2003-11-22

3.  Emergence in Klebsiella pneumoniae of a chromosome-encoded SHV beta-lactamase that compromises the efficacy of imipenem.

Authors:  Laurent Poirel; Claire Héritier; Isabelle Podglajen; Wladimir Sougakoff; Laurent Gutmann; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

4.  Evaluation of the Etest ESBL and the BD Phoenix, VITEK 1, and VITEK 2 automated instruments for detection of extended-spectrum beta-lactamases in multiresistant Escherichia coli and Klebsiella spp.

Authors:  Maurine A Leverstein-van Hall; Ad C Fluit; Armand Paauw; Adrienne T A Box; Sylvain Brisse; Jan Verhoef
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

5.  Epidemiological investigation of bloodstream infections by extended spectrum cephalosporin-resistant Escherichia coli in a Taiwanese teaching hospital.

Authors:  Jing-Jou Yan; Wen-Chien Ko; Jiunn-Jong Wu; Shu-Huei Tsai; Chin-Luan Chuang
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

Review 6.  Lemierre's Syndrome Caused by Klebsiella pneumoniae in a Diabetic Patient: A Case Report and Review of the Literature.

Authors:  Alan Chuncharunee; Thana Khawcharoenporn
Journal:  Hawaii J Med Public Health       Date:  2015-08

7.  European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia.

Authors:  Diana Averbuch; Christina Orasch; Catherine Cordonnier; David M Livermore; Malgorzata Mikulska; Claudio Viscoli; Inge C Gyssens; Winfried V Kern; Galina Klyasova; Oscar Marchetti; Dan Engelhard; Murat Akova
Journal:  Haematologica       Date:  2013-12       Impact factor: 9.941

8.  Evaluation of the current National Committee for Clinical Laboratory Standards guidelines for screening and confirming extended-spectrum beta-lactamase production in isolates of Escherichia coli and Klebsiella species from bacteremic patients.

Authors:  O T Katz; N Peled; P Yagupsky
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-10-08       Impact factor: 3.267

9.  Implementation of daily chlorhexidine bathing to reduce colonization by multidrug-resistant organisms in a critical care unit.

Authors:  Jackson S Musuuza; Ajay K Sethi; Tonya J Roberts; Nasia Safdar
Journal:  Am J Infect Control       Date:  2017-04-18       Impact factor: 2.918

Review 10.  Clinical role of beta-lactam/beta-lactamase inhibitor combinations.

Authors:  Nelson Lee; Kwok-Yung Yuen; Cyrus R Kumana
Journal:  Drugs       Date:  2003       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.